Abstract
The ideal treatment for ischemic stroke involves removal of vascular obstruction, protection of the injured brain, and restoration of function. Irreversible brain injury probably begins about 5 minutes after onset of complete global ischemia, which does not allow much scope for completely effective therapy.1 However, degrees of ischemia and vascular occlusion are variable in symptomatic patients, which means that some stroke patients can be helped considerably by aggressive treatment within the first few hours of onset. Measures aimed at improving perfusion pressure within the affected area of brain should be effective at limiting the degree of tissue damage following an ischemic event. The most obviously effective strategy would involve removal of the occlusive lesion (Fig. 13.1). Therefore, the possibility of thrombolytic therapy by intravenous and intraarterial routes has been examined in a number of trials. The earliest trials involved use of intravenous streptokinase administered to patients within periods up to 4 days following stroke. Treated groups of patients demonstrated poorer outcomes and higher rates of hemorrhagic transformation compared with controls.2
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Zivin JA (1998) Factors determining the therapeutic window for stroke. Neurology 50: 599–603.
Zivin JA (1999) Thrombolytic stroke therapy: past, present, and future. Neurology 53: 14–19.
Hacke W, Kaste M, Fieschi C, von Kummer R, Davalos A, Meier D, Larrue V, Bluhmki E, Davis S, Donnan G, Schneider D, Diez-Tejedor E, Trouillas P (1998) Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators. Lancet 352: 1245–1251.
Anonymous (1995) Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med 333: 1581–1587.
Clark WM, Albers GW (1999) The Atlantis rt-PA (Alteplase) Acute Stroke Trial: final results. Stroke 30: 234.
Edwards MT, Murphy MM, Geraghty JJ, Wulf JA, Konzen JP (1999) Intraarterial cerebral thrombolysis for acute isch- emic stroke in a community hospital. AJNR 20: 1682–1687.
Furlan A, Higashida R, Wechsler L, Gent M, Rowley H, Kase C, Pessin M, Ahuja A, Callahan F, Clark WM, Silver F, Rivera F (1999) Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial. JAMA 282: 2011.
Del Zoppo GJ, Higashida RT, Furlan AJ, Pessin MS, Row-Ley HA, Gent M (1998) PROACT: a phase II randomized trial of recombinant pro-urokinase by direct arterial delivery in acute middle cerebral artery stroke. PROACT Investigators. Prolyse in Acute Cerebral Thromboembolism. Stroke 29: 4–11.
Gönner F, Remonda L, Mattle H, Sturzenegger M, Ozdoba C, Lövblad KO, Baumgartner R, Bassetti C, Schroth G (1998) Local intra-arterial thrombolysis in acute ischemic stroke. Stroke 29: 1894–1900.
Jahan R, Gobin YP, Glenn B, Duckwiler GR, Vinuela F (1998) Transvenous embolization of a dural arteriovenous fistula of the cavernous sinus through the contralateral pterygoid plexus. Neuroradiology 40: 189–193.
Anonymous (1997) Intracerebral hemorrhage after intravenous t-PA therapy for ischemic stroke. The NINDS t-PA Stroke Study Group. Stroke 28: 2109–2118.
Von Kummer R, Bozzao L, Bastianello S, Manelfe C (1997) Extent of ischemic brain edema and the response to plas- minogen activators in acute hemispheric stroke. Stroke 28: 270.
Tomsick T, Brott T, Barsan W, Broderick J, Haley EC, Spilker J, Khoury J (1996) Prognostic value of the hyper-dense middle cerebral artery sign and stroke scale score before ultraearly thrombolytic therapy. AJNR 17: 79–85.
Lewandowski CA, Frankel M, Tomsick TA, Broderick J, Frey J, Clark W, Starkman S, Grotta J, Spilker J, Khory J, Brott T (1999) Combined intravenous and intraarterial r-TPA versus intraarterial therapy of acute ischemia stroke: Emergency Management of Stroke (EMS) Bridging Trial. Stroke 30: 2598–2605.
Qureshi AI, Suri FK, Shatla AA, Ringer AJ, Fessler RD, Ali Z, Guterman LR, Hopkins LN (2000) Intraarterial recombinant tissue plasminogen activator for ischemic stroke: an accelerating dosing regimen. Neurosurgery 47: 473–479.
Opatowsky MJ, Morris PP, Regan JD, Mewborne JD, Wil-Son JA (1999) Rapid thrombectomy of superior sagittal sinus and transverse sinus thrombosis with a rheolytic catheter device. AJNR 20: 414–417.
Dowd CF, Malek AM, Phatouros CC, Hemphill JC 3RD (1999) Application of a rheolytic thrombectomy device in the treatment of dural sinus thrombosis: a new technique. AJNR 20: 568–570.
Nakayama T, Tanaka K, Kaneko M, Yokoyama T, Uemura K (1998) Thrombolysis and angioplasty for acute occlusion of intracranial vertebrobasilar arteries. Report of three cases. J Neurosurg 88: 919–922.
The Abciximab IN Ischemic Stroke Investigators (2000) Abciximab in Acute Ischemic Stroke. A randomized, double-blind, placebo-controlled, dose-escalation study. Stroke 31: 601–609.
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2002 Springer Science+Business Media New York
About this chapter
Cite this chapter
Morris, P. (2002). Thrombolysis and Treatment of Acute Stroke. In: Interventional and Endovascular Therapy of the Nervous System. Springer, New York, NY. https://doi.org/10.1007/978-1-4757-3673-1_13
Download citation
DOI: https://doi.org/10.1007/978-1-4757-3673-1_13
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4419-2903-7
Online ISBN: 978-1-4757-3673-1
eBook Packages: Springer Book Archive